论文部分内容阅读
目的：测定白细胞介素-2受体（sIL．2R）含量，为肺结核的鉴别诊断及判断预后提供帮助。方法：应用ELISA双抗夹心法对肺结核。肺癌、急性肺炎的血清和购水进行SIL-2R含量测定。结果：（1）肺结核进展期与肺结核稳定期差异有显著意义（t=2.963，P＜0.01）。（2）肺结核复治组sIL-2R含量高于初治组，两者间差异有显著意义（t=2.305，P＜O.05）。（3）肺结核进展期、肺癌、肺炎患者sIL－2R含量均高于正常人，肺结核进展期与肺癌sIL-2R含量间差异有显著意义（t=3.122，P＜0．01）。（4）进展期肺结核血清sIL-2R含量与X线胸片范围和痰苗比较：波及4个肺野以上组sIL－2R含量最高，涉及1个肺野含量最低。瘦菌阳性组与痰菌阴性组sIL-2R含量，两组差异不显著。（5）进展期肺结核疫苗转阴和／或购片病变改善，其血清sIL-2R含量下降，胸片未改善和痰苗持续阳性者，sIL－2R含量不降低，反而呈增高趋势。（6）结核胸水与肺癌胸水sIL－2R含量，两者比较差异有显著意义（t=2.772，P＜0.05）。结论：测定肺结核患者血清sIL-2R含量，有助于对进展期肺结核疾病活动性及疗效的判断。
Objective: To determine the content of interleukin-2 receptor (sIL.2R), and to provide help for the differential diagnosis and prognosis of pulmonary tuberculosis. Methods: ELISA double-antibody sandwich method of tuberculosis. Lung cancer, serums from acute pneumonia and water purchase for SIL-2R determination. Results: (1) The difference between tuberculosis progression and tuberculosis stability was significant (t = 2.963, P <0.01). (2) The content of sIL-2R in tuberculosis retreatment group was higher than that in naive group, the difference was significant (t = 2.305, P <0.05). (3) The levels of sIL-2R in patients with lung cancer and pulmonary tuberculosis were significantly higher than those in controls (t = 3.122, P <0.01). (4) The content of sIL-2R in advanced pulmonary tuberculosis was significantly higher than that of X-ray and sputum in four lung fields. Leptospirosis positive group and sputum negative group sIL-2R content, the two groups showed no significant difference. (5) The incidence of sIL-2R in advanced pulmonary tuberculosis vaccine was negative, and / or the lesions of purchased tablets were improved. The serum sIL-2R level was decreased. (6) The contents of sIL-2R in tuberculous pleural effusion and lung cancer pleural effusion were significantly different (t = 2.772, P <0.05). Conclusion: Determination of serum sIL-2R levels in patients with tuberculosis, contribute to the judgment of activity and efficacy of advanced pulmonary tuberculosis.